Diagnostic Value of Serum hsa mir 92a in Patients with Cervical Cancer.
BACKGROUND Hsa mir 92a acts as an onco miRNA and may contribute to the progression and invasion of cervical cancer, which is a common malignant tumor in women worldwide. The objective of the present study was to evaluate whether serum hsa mir 92a could serve as a diagnostic biomarker for cervical cancer patients. METHODS The expression levels of hsa mir 92a were analyzed in the serum of patients with CIN I, CIN II, CIN III, cervical cancer Ia IIa and compared with those of the control group samples. The receiver operating characteristic (ROC) curve was used to evaluate the diagnostic significance of cervical cancer. RESULTS It was found that the expression of hsa miR 92a in the serum of individuals with CIN or cervical cancer was significantly higher than that in healthy volunteers (p 0.01) The expression of hsa miR 92a was higher in the serum of patients with advanced stage and cervical cancer than those with early stage. ROC analysis revealed that the cutoff value of hsa mir 92a was 1.52 for the diagnosis of CIN and cervical cancer. The sensitivity and specificity were 69.6% and 80.4% respectively, and an area under the curve (AUC) was 0.83. CONCLUSIONS hsa mir 92a up regulation was associated with cervical cancer and the serum level of hsa mir 92a could be used as an independent marker for the diagnosis of cervical cancer.
Clinical laboratory